March 15, 2019 07:16 AM EDT
Pharma

Roche clinch­es EU ap­proval for MabThera in rare au­toim­mune in­di­ca­tion — will it boost dwin­dling sales amid biosimi­ar com­pe­ti­tion?

Amber Tong

Roche is pil­ing up an­oth­er Eu­ro­pean ap­proval for its MabThera fran­chise just as biosim­i­lars are se­ri­ous­ly erod­ing sales of the cru­cial drug, bet­ter known in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times